This study was conducted to find out if etodolac, a cyclooxgenase-2 (COX-2)-specific inhibitor, could prevent chemically induced biliary carcinogenesis in bilioenterostomized hamsters. Syrian golden hamsters were subjected to choledochojejunostomy and then given subcutaneous injections of N-nitrosobis (2-oxopropyl)amine (BOP) 10 mg/kg body weight every 2 weeks. BOP was started 4 weeks after surgery, and continued for 18 weeks. The animals were simultaneously given etodolac 10 mg/kg body weight in 0.5% methylcellulose solution orally three times per week (etodolac group). The control hamsters were administered methylcellulose solution alone. The hamsters were killed 22 weeks after surgery, and the biliary carcinomas were examined histologically. The presence and degree of cholangitis and the cell kinetic status of the biliary epithelium were also evaluated with special reference to biliary carcinogenesis. Intrahepatic bile duct carcinomas developed in 15 (88%) of 17 hamsters in the control group, but in only 6 (33%) of 18 hamsters in the etodolac group (P < 0.01). The incidence and number of developing biliary carcinomas correlated well with the degree of cholangitis, and severe cholangitis was evident in the controls. The cell kinetic study demonstrated that the proliferating cell nuclear antigen-labeling index of the biliary epithelium was 9.67% in the control group and 5.14% in the etodolac group (P < 0.05). The mean levels of prostaglandin E2 (PGE2) products in the liver tissue were 14.14 ± 3.31 pg/total protein (TP) mg in the control group, and 7.46 ± 2.34 pg/TP mg in the etodolac group (P < 0.05). These findings indicated that etodolac inhibited the occurrence of severe cholangitis and the acceleration of biliary epithelial cell kinetics after bilioenterostomy, thereby preventing BOP-induced biliary carcinogenesis in hamsters. In conclusion, the COX-2-specific inhibitor, etodolac, could be used to prevent not only reflux cholangitis, but also biliary carcinoma after bilioenterostomy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Tocchi A., Costa G., Lepre L., Liotta G., Mazzoni G., Sita A. The long-term outcome of hepaticojejunostomy in the treatment of benign bile duct strictures. Ann. Surg. 1996 224:162–167.
Rothlin M.A., Lopfe M., Schlumpf R., Largiader F. Long-term results of hepaticojejunostomy for benign lesions of the bile ducts. Am. J. Surg. 1998 175:22–26.
Saing H., Han H., Chan K.L., Lam W., Chan F.L., Cheng W., Tam P.K. Early and late results of excision of choledochal cysts. J. Pediatr. Surg. 1997 32:1563–1566.
Uno K., Tsuchida Y., Kawarazaki H., Ohmiya H., Honna T.J. Development of intrahepatic cholelithiasis long after primary excision of choledochal cysts. Am. Coll. Surg. 1996 183:583–588.
Coyle K.A., Bradley E.L III. Cholangiocarcinoma developing after simple excision of type II choledochal cyst. South. Med. J. 1992 85:540–544.
Watanabe Y., Toki A., Todani T. Bile duct cancer developed after cyst excision for choledochal cyst. J. Hep. Bil. Pancr. Surg. 1999 6:207–212.
Strong R.W. Late bile duct cancer complicating biliary-enteric anastomosis for benign disease. Am. J. Surg. 1999 177:472–474.
Kitajima T., Tajima Y., Onizuka S., Matsuzaki S., Matsuo K., Kanematsu T. Linkage of persistent cholangitis after bilioenterostomy with biliary carcinogenesis in hamsters. J. Exp. Clin. Cancer Res. 2000 19:453–458.
Kitajima T., Tajima Y., Matsuzaki S., Kuroki T., Fukuda K., Kanematsu T. Acceleration of spontaneous biliary carcinogenesis in hamsters by bilioenterostomy. Carcinogenesis 2003 24:133–137.
Pollard M., Luckert P.H. Treatment of chemically-induced intestinal cancer with indometh-acin. Proc. Soc. Exp. Biol. Med. 1981 167:161–164.
Pollard M., Luckert P.H. Effect of indomethacin on intestinal tumor induced in rats by the acetate derivative of dimethylnitrosamine. Science 1981 214:558–559.
Reddy B.S., Rao C.V., Rivenson A., Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993 14:1493–1497.
Mahmoud N., Boolbol S., Dannenberg A., Mestre J., Bilinski R., Martucci C., Newmark H., Chadburn A., Bertagnolli M. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 1998 19:87–91.
Chiu C., McEntee M., Whelan J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res. 1997 57:4267–4273.
Oshima M., Dinchuk J., Kargman S., Oshima H., Hancock B., Kwong E., Trzaskos J., Evans J., Taketo M. Suppression of intestinal polyposis in Apc716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996 87:803–809.
Logan R.F.A., Little J., Hawtin P.G., Hardcastle J.D. Effect of aspirin and nonsteroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. Br. Med. J. 1993 307:285–289.
Kune G., Kune S., Watson L. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne colorectal cancer study. Cancer Res. 1988 48:4399–4404.
Thun M.J., Namboodiri M.M., Heath C.W. Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 1991 328:1593–1596.
Giovannucci E., Egan K., Hunter D., Stampfer M., Colditz G., Willett W., Speizer F. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 1995 333:609–614.
Winde G., Gumbinger H., Osswald H., Kemper F., Bunte H. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int. J. Colorectal Dis. 1993 8:13–17.
Winde G., Schmid K., Brandt B., Muller O., Osswald H. Clinical and genomic influence of sulindac and rectal mucosa in familial adenomatous polyposis. Dis. Colon Rectum 1997 40:1156–1168.
Matsuhashi N., Nakajima A., Fukushima Y., Yazaki Y., Oka T. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 1997 40:344–349.
Hayashi N., Yamamoto H., Hiraoka N., Dono K., Ito Y., Okami J., Kondo M., Nagano H., Umeshita K., Sakon M., Matsuura N., Nakamori S., Monden M. Differential expression of cyclooxgenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology 2001 34:638–650.
Chariyalertsak S., Sirikulchayanonta V., Mayer D., Kopp-Schneider A., Fürstenberger G., Marks F., Müller-Decker K. Aberrant cyclooxgenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut 2001 48:80–86.
Tsuneoka N., Tajima Y., Kitazato A., Fukuda K., Kitajima T., Kuroki T., Onizuka S., Kanematsu T. Chemopreventative effect of a cyclooxygenase-2-specific inhibitor (etodolac) on chemically induced biliary carcinogenesis in hamsters. Carcinogenesis 2005 26:465–469.
Pour P., Althoff J., Kruger F.W., Mohr U. A potent pancreatic carcinogen in Syrian hamsters: N-nitrosobis(2-oxopropyl)amine. J. Natl. Cancer Inst. 1977 58:1449–1453.
Tajima Y., Eto T., Tsunoda T., Tomioka T., Inoue K., Fukahori T., Kanematsu T. Induction of extrahepatic biliary carcinoma by N-nitrosobis(2-oxopropyl)amine in hamsters given cholecystoduodenostomy with dissection of the common duct. Jpn. J. Cancer Res. 1994 85(8):780–788.
Kishimoto Y., Tanaka N., Jinnai T., Morisawa T., Shiota G., Kawasaki H., Hasegawa T. Sulindac and a cyclooxgenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane. Gut 2000 47:812–819.
Inoue K., Fujisawa H., Sasaki Y., Nishimura T., Nishimura I., Inoue Y., Yokota M., Masuda T., Ueda F., Shibata Y. Pharmacological properties of the new non-steroidal anti-inflammatory agent etodolac. Arzneimittelforschung 1991 41:228–235.
Fukuda K., Kuroki T., Tajima Y., Tsuneoka N., Kitajima T., Matsuzaki S., Furui J., Kanematsu T. Comparative analysis of Helicobacter DNAs and biliary pathology in patients with and without hepatobiliary cancer. Carcinogenesis 2002 23:1927–1931.
Zhigng L., Yutaka S., Atsushi K., Fumiaki S., Masato M., Izumi K., Tao H., Yongzeng D., Junichi K., Masayuki I. Suppression of N-nitrosomethyl- benzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis 2001 22:547–551.
Hu P.J., Yu J., Zeng Z.R., Leung W.K., Lin H.L., Tang B.D., Bai A.H., Sung J.J. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004 53:195–200.
Furukawa F., Nishikawa A., Lee I.S., Kanki K., Umemura T., Okazaki K., Kawamori T., Wakabayashi K., Hirose M. A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters. Int. J. Cancer 2003 104:269–273.
Ogura Y., Matsuda S., Ito M., Niimi R., Sumitomo M., Kawarada Y. Chemoprevention of biliary carcinogenesis in Syrian hamsters by the novel carboxamide IS-741 after initiation with N-nitrosobis(2-oxopropyl)amine (BOP). Carcinogenesis 2000 21:1469–1475.
Yunjie S., Xi M.T., Elizabeth Half M., Tien K., Frank A.S. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 2002 62:6323–6328.
Michael K.J., Hongtao W., Brigitta M.P., Ellis L., Rabiha M.I., James S., Andrzej S.T. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanism and implications for cancer growth and ulcer healing. Nat. Med. 1999 5:1418–1424.
Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., Dubois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1988 93:705–716.
Tsuchida A., Nagakawa Y., Kasuya K., Itoi T., Endo M., Ozawa T., Aoki T., Koyanagi Y. Immunohistochemical analysis of cyclooxygenase-2 and vascular endothelial growth factor in pancreaticobiliary maljunction. Oncol. Rep. 2003 2:339–343.
Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971 231:232–235.
Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestional toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. U. S. A. 1999 96:7563–7568.
Kim S.H., Lee S.E., Oh H., Kim S.R., Yee S.T., Yu Y.B., Byun M.W., Jo S.K. The radioprotective effects of bu-zhong-yi-qi-tang: a prescription of traditional Chinese medicine. Am. J. Chin. Med. 2002 30:127–137.
Kaneko M., Kawakita T., Kumazawa Y., Takimoto H., Nomoto K., Yoshikawa T. Accelerated recovery from cyclophosphamide-induced leukopenia in mice administered a Japanese ethical herbal drug, Hochu-ekki-to. Immunopharmacology 1999 44:223–231.
Cho J.M., Sato N., Kikuchi K. Prophylactic anti-tumor effect of Hochu-ekki-to (TJ41) by enhancing natural killer cell activity. In Vivo 1991 5:389–391.
Ohnishi Y., Fujii H., Hayakawa Y., Sakukawa R., Yamaura T., Sakamoto T., Tsukada K., Fujimaki M., Nunome S., Komatsu Y., Saiki I. Oral administration of a kampo (Japanese herbal) medicine Juzen-taiho-to inhibits liver metastasis of colon 26-L5 carcinoma cells. Jpn. J. Cancer Res. 1998 9:206–213.
Utsuyama M., Seidlar H., Kitagawa M., Hirokawa K. Immunological restoration and anti-tumor effect by Japanese herbal medicine in aged mice. Mech. Ageing Dev. 2001 122:341–352.
Onishi Y., Yamaura T., Tauchi K., Sakamoto T., Tsukada K., Nunome S., Komatsu Y., Saiki I. Expression of the anti-metastatic effect induced by Juzen-taiho-to is based on the content of Shimotsu-to constituents. Biol. Pharm. Bull. 1998 21:761–765.
Harada M., Seta K., Ito O., Tamada K., Li T., Terao H., Takenoyama M., Kimura G., Nomoto K. Concomitant immunity against tumor development is enhanced by the oral administration of a Kampo medicine, Hochu-ekki-to (TJ-41: Bu-Zhong-Yi-Qi-Tang). Immunopharmacol. Immunotoxicol. 1995 17:687–703.
Kao S.T., Yeh C.C., Hsieh C.C., Yang M.D., Lee M.R., Liu H.S., Lin J.G. The Chinese medicine Bu-Zhong-Yi-Qi-Tang inhibited proliferation of hepatoma cell lines by inducing apoptosis via G0/G1 arrest. Life Sci. 2001 69:1485–1496.
Zhu K., Fukasawa I., Furuno M., Inaba F., Yamazaki T., Kamemori T., Kousaka N., Ota Y., Hayashi M., Maehama T., Inaba N. Inhibitory effects of herbal drugs on the growth of human ovarian cancer cell lines through the induction of apoptosis. Gynecol. Oncol. 2005 97:405–409.
Onogi K., Niwa K., Tang L., Yun W., Mori H., Tamaya T. Inhibitory effects of Hochu-ekki-to on endometrial carcinogenesis induced by N-methyl-N- nitrosourea and 17beta-estradiol in mice. Oncol. Rep. 2006 16:1343–1348.
Moore M.A., Thamavit W., Bannasch P. Tumours of the liver. In Pathology of tumours in laboratory animals, V.S. Turusov and U. Mohr, eds., Vol. 3, Tumours of the hamster, 2/e. Lyon: International Agency for Research on Cancer, 1996, pp. 79–108.
Ohta T., Nagakawa T., Ueda N., Nakamura T., Akiyama T., Ueno K., Miyazaki I. Mucosal dysplasia of the liver and the intraductal variant of peripheral cholangiocarcinoma in hepatolithiasis. Cancer 1991 68:2217–2223.
Falchuk K.R., Lesser P.B., Galdabini J.J., Isselbacher KJ. Cholangiocarcinoma as related to chronic intrahepatic cholangitis and hepatolithiasis. Case report and review of the literature. Am. J. Gastroenterol. 1976 66:57–61.
Chijiiwa K., Ichimiya H., Kuroki S., Koga A., Nakamura F. Late development of cholangi-ocarcinoma after the treatment of hepatolithiasis. Surg. Gynecol. 1993 177:279–282.
Holzinger F., Z'graggen K., Büchler M.W. Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma. Ann. Oncol. 1999 10:122–126.
Chapman R.W. Risk factors for biliary tract carcinogenesis. Ann. Oncol. 1999 10:308–311.
Taniai M., Higuchi H., Burgart L.J., Gores G.J. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002 123:1090–1098.
Mori K., Kido T., Daikuhara H., Sakakibara I., Sakata T., Shimizu K., Amagaya S., Sasaki H., Komatsu Y. Effect of hochu-ekki-to (TJ-41), a Japanese herbal medicine, on the survival of mice infected with influenza virus. Antivir. Res. 1999 44:103–111.
Hai le X., Kogure T., Niizawa A., Fujinaga H., Sakakibara I., Shimada Y., Watanabe H., Terasawa K. Suppressive effect of hochu-ekki-to on collagen induced arthritis in DBA1J mice. J. Rheumatol. 2002 29:1601–1608.
Furuya Y., Akashi T., Fuse H. Effect of Bu-zhong-yi-qi-tang on seminal plasma cytokine levels in patients with idiopathic male infertility. Arch. Androl. 2004 50:11–14.
Tsuneoka N., Tajima Y., Kitasato A., Fukuda K., Kitajima T., Adachi T., Mishima T., Kuroki T., Onizuka S., Kanematsu T. Chemopreventative effect of hochu-ekki-to (TJ41) on chemically induced biliary carcinogenesis in hamsters. J Surg Res. 2008 Feb 1. [Epub ahead of print]
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer
About this chapter
Cite this chapter
Tsuneoka, N. et al. (2009). Chemoprevention of Biliary Carcinogenesis. In: Tajima, Y., Kuroki, T., Kanematsu, T. (eds) Hepatobiliary and Pancreatic Carcinogenesis in the Hamster. Springer, Tokyo. https://doi.org/10.1007/978-4-431-87773-8_10
Download citation
DOI: https://doi.org/10.1007/978-4-431-87773-8_10
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-87772-1
Online ISBN: 978-4-431-87773-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)